Investors sold shares of Eli Lilly and Company (NYSE:LLY) on strength during trading on Friday following insider selling activity. $47.72 million flowed into the stock on the tick-up and $84.82 million flowed out of the stock on the tick-down, for a money net flow of $37.10 million out of the stock. Of all equities tracked, Eli Lilly and Company had the 26th highest net out-flow for the day. Eli Lilly and Company traded up $0.94 for the day and closed at $81.04Specifically, insider Melissa S. Barnes sold 1,900 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $80.78, for a total transaction of $153,482.00. Following the sale, the insider now owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Michael J. Harrington sold 22,833 shares of the business’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the sale, the vice president now directly owns 62,056 shares in the company, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. Insiders sold 259,733 shares of company stock worth $21,829,137 over the last three months. 0.20% of the stock is currently owned by insiders.

LLY has been the topic of several analyst reports. Jefferies Group LLC reissued a “buy” rating and issued a $97.00 price objective (up previously from $95.00) on shares of Eli Lilly and Company in a research note on Saturday, March 11th. Citigroup Inc. restated a “buy” rating and issued a $100.00 target price on shares of Eli Lilly and Company in a report on Thursday, April 6th. Zacks Investment Research upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $94.00 target price on the stock in a report on Tuesday, April 4th. Credit Suisse Group restated a “buy” rating on shares of Eli Lilly and Company in a report on Tuesday, March 21st. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $100.00 target price on shares of Eli Lilly and Company in a report on Monday, April 17th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $87.59.

The company has a market capitalization of $86.49 billion, a PE ratio of 39.59 and a beta of 0.36. The firm’s 50-day moving average price is $80.08 and its 200-day moving average price is $78.91.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 25th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.96 by $0.02. Eli Lilly and Company had a net margin of 10.13% and a return on equity of 26.64%. The company had revenue of $5.23 billion for the quarter, compared to the consensus estimate of $5.22 billion. During the same quarter in the prior year, the firm earned $0.83 earnings per share. Eli Lilly and Company’s revenue was up 7.5% on a year-over-year basis. On average, analysts anticipate that Eli Lilly and Company will post $4.12 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, June 9th. Stockholders of record on Monday, May 15th were paid a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.54%. The ex-dividend date of this dividend was Thursday, May 11th. Eli Lilly and Company’s dividend payout ratio is currently 100.48%.

Large investors have recently made changes to their positions in the stock. First Command Financial Services Inc. increased its stake in shares of Eli Lilly and Company by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares in the last quarter. Heritage Trust Co purchased a new stake in shares of Eli Lilly and Company during the first quarter valued at $135,000. LeJeune Puetz Investment Counsel LLC purchased a new stake in shares of Eli Lilly and Company during the fourth quarter valued at $136,000. Point72 Asia Hong Kong Ltd increased its stake in shares of Eli Lilly and Company by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares in the last quarter. Finally, Penserra Capital Management LLC increased its stake in shares of Eli Lilly and Company by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after buying an additional 176 shares in the last quarter. 75.44% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Traders Sell Shares of Eli Lilly and Company (LLY) on Strength on Insider Selling” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/06/16/investors-sell-eli-lilly-and-co-lly-on-strength-after-insider-selling-updated.html.

Eli Lilly and Company Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.